171 related articles for article (PubMed ID: 37807065)
1. Risks of non-ovarian cancers in women with borderline ovarian tumor: a national cohort study in Sweden.
Dobilas A; Jansåker F; Li X; Sundquist K; Borgfeldt C
BMC Cancer; 2023 Oct; 23(1):951. PubMed ID: 37807065
[TBL] [Abstract][Full Text] [Related]
2. Risk of specific types of ovarian cancer after borderline ovarian tumors in Denmark: A nationwide study.
Hannibal CG; Frederiksen K; Vang R; Kurman RJ; Kjaer SK
Int J Cancer; 2020 Aug; 147(4):990-995. PubMed ID: 31930502
[TBL] [Abstract][Full Text] [Related]
3. Risk of nonovarian cancer in a nationwide-based study of nearly 5000 women with borderline ovarian tumors in Denmark.
Hannibal CG; Baandrup L; Hertzum-Larsen R; Vang R; Kurman RJ; Frederiksen K; Kjaer SK
Int J Cancer; 2023 Apr; 152(7):1370-1377. PubMed ID: 36366853
[TBL] [Abstract][Full Text] [Related]
4. Italian cancer figures, report 2013: Multiple tumours.
AIRTUM Working Group
Epidemiol Prev; 2013; 37(4-5 Suppl 1):1-152. PubMed ID: 24259384
[TBL] [Abstract][Full Text] [Related]
5. Risk of borderline ovarian tumors among women with benign ovarian tumors: A cohort study.
Guleria S; Jensen A; Kjær SK
Gynecol Oncol; 2018 Jan; 148(1):86-90. PubMed ID: 29174556
[TBL] [Abstract][Full Text] [Related]
6. Borderline ovarian tumors: French guidelines from the CNGOF. Part 1. Epidemiology, biopathology, imaging and biomarkers.
Huchon C; Bourdel N; Abdel Wahab C; Azaïs H; Bendifallah S; Bolze PA; Brun JL; Canlorbe G; Chauvet P; Chereau E; Courbiere B; De La Motte Rouge T; Devouassoux-Shisheboran M; Eymerit-Morin C; Fauvet R; Gauroy E; Gauthier T; Grynberg M; Koskas M; Larouzee E; Lecointre L; Levêque J; Margueritte F; Mathieu D'argent E; Nyangoh-Timoh K; Ouldamer L; Raad J; Raimond E; Ramanah R; Rolland L; Rousset P; Rousset-Jablonski C; Thomassin-Naggara I; Uzan C; Zilliox M; Daraï E
J Gynecol Obstet Hum Reprod; 2021 Jan; 50(1):101965. PubMed ID: 33160106
[TBL] [Abstract][Full Text] [Related]
7. Borderline Ovarian Tumors Share Familial Risks with Themselves and Invasive Cancers.
Zheng G; Yu H; Kanerva A; Försti A; Sundquist K; Hemminki K
Cancer Epidemiol Biomarkers Prev; 2018 Nov; 27(11):1358-1363. PubMed ID: 30018148
[No Abstract] [Full Text] [Related]
8. Second neoplasms after invasive and borderline ovarian cancer.
Levi F; Randimbison L; Blanc-Moya R; La Vecchia C
Eur J Cancer Prev; 2009 Jun; 18(3):216-9. PubMed ID: 19491608
[TBL] [Abstract][Full Text] [Related]
9. Borderline ovarian tumors: Guidelines from the French national college of obstetricians and gynecologists (CNGOF).
Bourdel N; Huchon C; Abdel Wahab C; Azaïs H; Bendifallah S; Bolze PA; Brun JL; Canlorbe G; Chauvet P; Chereau E; Courbiere B; De La Motte Rouge T; Devouassoux-Shisheboran M; Eymerit-Morin C; Fauvet R; Gauroy E; Gauthier T; Grynberg M; Koskas M; Larouzee E; Lecointre L; Levêque J; Margueritte F; Mathieu D'argent E; Nyangoh-Timoh K; Ouldamer L; Raad J; Raimond E; Ramanah R; Rolland L; Rousset P; Rousset-Jablonski C; Thomassin-Naggara I; Uzan C; Zilliox M; Daraï E
Eur J Obstet Gynecol Reprod Biol; 2021 Jan; 256():492-501. PubMed ID: 33262005
[TBL] [Abstract][Full Text] [Related]
10. Incidence of cancer among patients with atopic dermatitis.
Hagströmer L; Ye W; Nyrén O; Emtestam L
Arch Dermatol; 2005 Sep; 141(9):1123-7. PubMed ID: 16172309
[TBL] [Abstract][Full Text] [Related]
11. Risk of ovarian cancer in women treated with ovarian stimulating drugs for infertility.
Rizzuto I; Behrens RF; Smith LA
Cochrane Database Syst Rev; 2019 Jun; 6(6):CD008215. PubMed ID: 31207666
[TBL] [Abstract][Full Text] [Related]
12. Subsequent primary malignancies after endometrial carcinoma and ovarian carcinoma.
Hemminki K; Aaltonen L; Li X
Cancer; 2003 May; 97(10):2432-9. PubMed ID: 12733142
[TBL] [Abstract][Full Text] [Related]
13. Borderline ovarian tumors: French guidelines from the CNGOF. Part 2. Surgical management, follow-up, hormone replacement therapy, fertility management and preservation.
Bourdel N; Huchon C; Abdel Wahab C; Azaïs H; Bendifallah S; Bolze PA; Brun JL; Canlorbe G; Chauvet P; Chereau E; Courbiere B; De La Motte Rouge T; Devouassoux-Shisheboran M; Eymerit-Morin C; Fauvet R; Gauroy E; Gauthier T; Grynberg M; Koskas M; Larouzee E; Lecointre L; Levêque J; Margueritte F; D'argent Mathieu E; Nyangoh-Timoh K; Ouldamer L; Raad J; Raimond E; Ramanah R; Rolland L; Rousset P; Rousset-Jablonski C; Thomassin-Naggara I; Uzan C; Zilliox M; Daraï E
J Gynecol Obstet Hum Reprod; 2021 Jan; 50(1):101966. PubMed ID: 33144266
[TBL] [Abstract][Full Text] [Related]
14. Assisted reproductive technology and risk of ovarian cancer and borderline tumors in parous women: a population-based cohort study.
Lundberg FE; Johansson ALV; Rodriguez-Wallberg K; Gemzell-Danielsson K; Iliadou AN
Eur J Epidemiol; 2019 Nov; 34(11):1093-1101. PubMed ID: 31377935
[TBL] [Abstract][Full Text] [Related]
15. Long-term survival in women with borderline ovarian tumors: a population-based survey of borderline ovarian tumors in Sweden 1960-2007.
Kalapotharakos G; Högberg T; Bergfeldt K; Borgfeldt C
Acta Obstet Gynecol Scand; 2016 Apr; 95(4):473-9. PubMed ID: 26714557
[TBL] [Abstract][Full Text] [Related]
16. Menopausal hormone therapy and cancer risk: An overestimated risk?
Simin J; Tamimi R; Lagergren J; Adami HO; Brusselaers N
Eur J Cancer; 2017 Oct; 84():60-68. PubMed ID: 28783542
[TBL] [Abstract][Full Text] [Related]
17. Increased risk of second primary malignancies in patients with gynecological cancer. A Swedish record-linkage study.
Bergfeldt K; Einhorn S; Rosendahl I; Hall P
Acta Oncol; 1995; 34(6):771-7. PubMed ID: 7576744
[TBL] [Abstract][Full Text] [Related]
18. Risks of ovarian, breast, and corpus uteri cancer in women treated with assisted reproductive technology in Great Britain, 1991-2010: data linkage study including 2.2 million person years of observation.
Williams CL; Jones ME; Swerdlow AJ; Botting BJ; Davies MC; Jacobs I; Bunch KJ; Murphy MFG; Sutcliffe AG
BMJ; 2018 Jul; 362():k2644. PubMed ID: 29997145
[TBL] [Abstract][Full Text] [Related]
19. Acromegaly and cancer risk: a cohort study in Sweden and Denmark.
Baris D; Gridley G; Ron E; Weiderpass E; Mellemkjaer L; Ekbom A; Olsen JH; Baron JA; Fraumeni JF
Cancer Causes Control; 2002 Jun; 13(5):395-400. PubMed ID: 12146843
[TBL] [Abstract][Full Text] [Related]
20. Impact of levonorgestrel-releasing intrauterine system use on the cancer risk of the ovary and fallopian tube.
Soini T; Hurskainen R; Grénman S; Mäenpää J; Paavonen J; Pukkala E
Acta Oncol; 2016 Nov; 55(11):1281-1284. PubMed ID: 27148621
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
